Previous Article |
Table of Contents
| Next Article 
§ Cecil H. and Ida Green Center for Reproductive
Biology Sciences, * Howard Hughes Medical Institute, and
Contributed by David L. Garbers, December 28, 2000
Guanylyl cyclase-A (NPR-A; GC-A) is the major and possibly the only
receptor for atrial natriuretic peptide (ANP) or B-type natriuretic
peptide. Although mice deficient in GC-A display an elevated blood
pressure, the resultant cardiac hypertrophy is much greater than in
other mouse models of hypertension. Here we overproduce GC-A in the
cardiac myocytes of wild-type or GC-A null animals. Introduction of the
GC-A transgene did not alter blood pressure or heart rate as a function
of genotype. Cardiac myocyte size was larger (approximately 20%) in
GC-A null than in wild-type animals. However, introduction of the GC-A
transgene reduced cardiac myocyte size in both wild-type and null mice. Coincident with the reduction in myocyte size, both ANP mRNA and ANP
content were significantly reduced by overexpression of GC-A, and this
reduction was independent of genotype. This genetic model, therefore,
separates a regulation of cardiac myocyte size by blood pressure from
local regulation by a GC-mediated pathway.
Atrial natriuretic peptide
(ANP) is a circulating hormone synthesized in and secreted from the
heart (1-3). Biological actions of administered ANP include a
stimulation of natriuresis, diuresis, and vasorelaxation, and an
inhibition of renin and aldosterone secretion (4-7). Under normal
conditions, ANP is synthesized, stored in granules, and secreted mainly
by atrial myocytes. However, during various cardiac pathologies,
ventricular myocytes undergo important phenotypic modifications that
result in the expression of several fetal genes (e.g., ANP) and
hypertrophy (8).
Guanylyl cyclase-A (NPR-A; GC-A), a membrane enzyme that contains a
peptide-binding, protein kinase homology and GC catalytic homology
domain, is thought to be the principal and possibly the only receptor
for ANP. The peptide binds to GC-A with high affinity and fails to
cause relaxation of precontracted aortic rings or a
natriuretic/diuretic response in GC-A null mice (9-13).
The inhibition of specific signaling pathways has represented a
classical means by which to define the function of such pathways. Gene
disruption is one method by which to interrupt signaling pathways, and
we and others have disrupted the genes for ANP, B-type natriuretic
peptide (BNP), or GC-A (14-17). Disruption of the GC-A gene results in
mice that display a salt-resistant elevation of blood pressure, and
cardiac fibrosis and hypertrophy (16, 17). The cardiac hypertrophy is
greater than that seen in other mouse models of hypertension (18),
suggesting that GC-A could be directly involved in the regulation of
myocyte size. It has been shown, in fact, that ANP inhibits
cardiomyocyte hypertrophy under in vitro culture conditions
(19-22).
In these studies, we design a genetic mouse model where GC-A null mice
are crossed with mice expressing GC-A as a transgene specifically in
cardiac myocytes. Based on studies of these mice, we suggest that
cardiac myocyte GC-A can act as a negative regulator of myocyte size
independently of blood pressure.
Production of GC-A Null Mice.
Mice deficient for GC-A were produced and maintained on a C57BL/6
background as previously described (16).
Production of GC-A Transgenic Mice.
The cDNA insert for the mouse GC-A gene was cloned into a
SalI-digested
Medical Sciences
A genetic model provides evidence that the receptor for atrial
natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular
myocyte hypertrophy
,
,,§, and,§,¶
Department of Pharmacology, University of Texas
Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX
75390-9051
Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-myosin heavy chain promoter construct (a
generous gift from J. Robbins, Dept. of Pharmacology and Cell
Biophysics, University of Cincinnati) (23). The vector contains a
5.8-kb BamHI-MaeIII fragment of the murine
-myosin heavy chain gene that includes the promoter and exons 1-3
from the 5' untranslated region of the gene and a human growth hormone
polyadenylation site (Fig. 1). The vector
sequence was removed by digestion with NotI. The linear
fragment was gel-purified, eluted with the use of Qiaquick columns
(Qiagen, Chatsworth, CA), and injected into the male pronucleus of
fertilized, single-cell B6C3F1 strain embryos. Stable founder lines
were identified initially by Southern analysis and subsequently by PCR
with the use of primers specific for the transgene. Two founders
transmitted the transgene to offspring. Similar results were obtained
for the two lines of mice. All aspects of animal care and
experimentation performed in this study were approved by the Animal
Resources Center of the Southwestern Medical Center at Dallas.
View larger version (16K):
[in a new window]
Fig. 1.
Schematic diagram showing the construct used for production of GC-A
transgenic mouse lines. The line labeled "probe" represents the
portion of the mouse GC-A cDNA used in Southern or Northern analyses.
MHC, myosin heavy chain.
-myosin heavy chain promoter drives transgenes exclusively in
cardiac myocytes and has been used extensively in previous transgenic
studies (24, 25). In the atrium, this promoter is expressed in both
embryonic and adult myocytes. However, its expression in ventricular
myocytes is observed mainly after birth (26, 27).
GC-A null mice and GC-A transgenic mice were crossed to produce GC-A
null mice with cardiac-specific expression of GC-A. Male and female
mice 3-6 months of age (24-34 g body weight) were studied, and no
apparent gender differences in ratios of heart weight to body weight
were seen.
Blood Pressure and Heart Rate. Blood pressures and heart rates of mice were determined with a BP-98A (Softron, Tokyo, Japan) as previously described (16).
Isolation of Cardiomyocytes. The cardiac myocytes were enzymatically dissociated from the mouse heart as in previous published protocols, with minor modifications (28). Briefly, 4-month-old mice were heparinized (5 units/g body weight) with an intraperitoneal injection. After 30 min, mice were anesthetized with metofane inhalation, and immediately after excision of the heart, it was placed in PBS. After cannulation of the aortic root, the heart was retrogradely perfused with a solution containing type I collagenase (0.17%) and 10 mM 2,3-butanedione monoxamine in PBS preequilibrated with 100% O2. The tissue was then removed from the cannula, and ventricles were minced and triturated in PBS. The temperature was kept at 37°C throughout the isolation procedure. Freshly isolated myocytes were fixed with 10% formalin in PBS. That the preparation represented cardiac myocytes was verified by fixing the cells, permeabilizing them, staining their nuclei with 4',6-diamidino-2'-phenylindole dihydrochloride (1 µg/ml), and visualizing them by fluorescence microscopy. Nuclei of cardiac myocytes have a characteristic elongated shape that distinguishes them from those of fibroblasts or endothelial cells.
Cardiomyocyte Area. The average planar area of a two-dimensional silhouette of the cardiomyocyte was determined by tracing approximately 100 randomly selected myocytes per heart from ventricular fractions. The outer borders of the myocytes were traced, and the myocyte areas were calculated. The averaged value was used in subsequent analysis.
Determination of Ventricular ANP and mRNA Content. The hearts were removed after cervical dislocation and were immediately frozen in liquid nitrogen. The lysates were obtained by homogenization in ice-cold buffer (1% Nonidet P-40/10% glycerol/137 mM NaCl/20 mM Tris·HCl, pH 7.4/4 µg/ml aprotinin/4 µg/ml leupeptin/1 mM PMSF/4 µg/ml pepstatin/20 mM NaF/1 mM sodium pyrophosphate/1 mM orthovanadate). The lysates were kept on ice for 15 min and cleared by centrifugation at 15,000 × g for 20 min at 4°C. Protein concentration was determined by the Bradford method (Bio-Rad). ANP contents of the cardiac ventricles were determined by a commercially available specific RIA (Peninsula Laboratories) according to the manufacturer's instructions. Total RNA was extracted from flash-frozen ventricles with the use of RNA-STAT (Tel-Test, Friendship, TX), and ANP mRNA levels of the ventricles were determined by Northern blot analysis with a specific probe for mouse ANP cDNA.
Data Analysis. Data are reported as means ± SEMs of more than triplicate separate experiments. Statistical significance was determined by Student's unpaired t test.
| |
Results |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
The average ratio of heart weight (mg) to body weight (g) of GC-A
null mice at 2-6 months of age was increased to 131% of that of
wild-type littermates (n = 14) (not shown). To
determine whether myocardial GC-A could alter myocyte size in the
potential absence of hemodynamic changes, transgenic animals
overexpressing mouse GC-A under the control of the mouse -myosin
heavy chain promoter were generated (Fig. 1). Southern blot analysis
revealed that genomic DNA from transgenic mice contains multiple copies of the construct (Fig. 2a).
The cardiac GC-A mRNA content of transgenic mice was much higher than
that of nontransgenic littermates, whereas there was no apparent
genotypic change in GC-A mRNA levels in the aorta or in the kidney
(Fig. 2b).
|
As we have previously reported, the systolic blood pressure of GC-A null mice is higher than that of wild-type mice (122 ± 3.4 mmHg and 94 ± 4.5 mmHg, respectively; P < 0.01). Systolic blood pressure did not change significantly in the presence of the transgene in either wild-type or GC-A null genetic backgrounds (Fig. 3a). There also was no significant change in heart rate between the different genotypes (Fig. 3b). Thus, no hemodynamic change appears to have occurred in the cardiac-specific GC-A transgenic mice.
|
There was a significant increase in the ratio of heart weight (mg) to body weight (g) of the GC-A null mice compared with that of wild-type mice (P = 0.006) (Fig. 4a). The ratio of heart weight to body weight of transgenic mice was significantly less than that of the nontransgenic littermates (4.62 ± 0.23 and 5.33 ± 0.26, respectively; P < 0.03). On the GC-A null background, however, no significant difference between the ratios of heart weight to body weight was seen in the absence or presence of the transgene (7.01 ± 0.45 and 6.71 ± 0.63, respectively; P < 0.4).
|
To determine whether GC-A overexpression reduces cardiomyocyte size, we
next measured areas of freshly isolated cardiomyocytes. The average
cardiomyocyte area of GC-A null mice was significantly increased
compared with that of wild-type mice (6.05 ± 0.26 and 5.15 ± 0.14 × 10
5
mm2/g body weight, respectively) as shown in
Fig. 4b. With cardiac overexpression of GC-A, the average
cardiomyocyte area was decreased either in the wild-type background
(4.78 ± 0.18 × 105
mm2/g body weight) or the GC-A null background
(5.5 ± 0.5 × 105
mm2/g body weight) relative to mice not
carrying the GC-A transgene.
Because cardiac hypertrophy is accompanied by an activation of the cardiac fetal gene program in the ventricle and reexpression of ANP is one of the best markers of this change (29, 30), we next examined ventricular expression of ANP and of ANP mRNA. Ventricular ANP concentrations in GC-A null mice were 8-fold higher than that of wild-type mice (10.9 ± 4.9 and 1.26 ± 0.29 ng/mg protein, respectively) (Fig 5a). Cardiac overexpression of GC-A reduced ventricular ANP concentrations to approximately 30% in both wild-type and GC-A null mice. A similar effect was seen with respect to ventricular ANP mRNA levels (Fig. 5b), also compatible with the constitutive secretory pathway of ventricular ANP (31).
|
There were strong correlations between ANP content and ANP mRNA levels (Fig. 6a) and between ANP content and cardiomyocyte size (Fig. 6b). Whereas there appeared to be a linear relationship between ANP mRNA and ANP levels, the relationship between ANP and cardiomyocyte area to body weight was exponential in nature. Thus, as cardiomyocyte area increased, a disproportionate increase in ANP occurred, reflecting the activation of a fetal gene expression program. Ventricular BNP was also reduced somewhat in GC-A transgenic animals, but the effects were much less dramatic than with ANP (data not shown).
|
| |
Discussion |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
GC-A-deficient mice display a marked cardiac hypertrophy, which in general is much greater than that seen in other mouse models of hypertension (17, 18). The phenotype has suggested the possibility that the GC-A signaling pathway is an important component in the regulation of cardiac myocyte size independent of blood pressure.
Here a GC-A transgene expressed within the cardiac myocyte failed to significantly alter blood pressures of either wild-type or GC-A null mice, and yet cardiomyocyte size was significantly reduced when the transgene was expressed in either genotype. Therefore, the GC-A signaling pathway appears to protect against cardiac myocyte hypertrophy. Whether the protection is facilitated by ANP or BNP stimulation of the enzyme is not known. Previous mouse models where ANP or BNP was introduced as a transgene (32, 33) or where the peptide genes were disrupted (14, 15) have been often confounded with alterations in blood pressure, as is also the case for the GC-A gene disruption (16, 17). Thus changes in cardiac size are likely due to a combination of local and pressure-induced signaling pathways in these genetic models. The experiments here appear to finally separate blood pressure signaling pathways from other pathways that regulate myocyte size, namely that involving GC-A.
That the GC-A or GC-B signaling pathways can inhibit cell proliferation has been reported by numerous groups (34-36), and recently Chrisman and colleagues (37) also have shown a dramatic and rapid desensitization of GC-B by various growth factors or serum. The soluble forms of GC, in contrast, were not acutely affected by the growth factors or serum. It has been suggested, therefore, that a strong adversarial relationship exists between growth factor and particulate GC signaling pathways (37). Given that GC-A null mice display a prominent cardiac hypertrophy and fibrosis (17, 18), it is possible that the elimination of GC-A results in a loss of control over growth factor-induced cardiomyocyte hypertrophy and fibroblast proliferation in the heart.
In addition to cardiomyocyte hypertrophy, the increase in heart weight of GC-A null mice could also be due to an increase in cardiomyocyte number. Because ANP has been suggested to induce apoptosis in rat neonatal cardiomyocytes (38), the absence of ANP/BNP-induced elevations of cGMP in GC-A-deficient mice could lead to decreased numbers of apoptotic cardiac myocytes, resulting in increased total myocyte numbers. This increase in myocytes would likely arise from either a decrease in apoptosis during embryogenesis or additional rounds of replication. This study did not directly address myocyte numbers.
Because cardiac hypertrophy protects against ventricular pressure overload, reversal of hypertrophy with GC-A overexpression in the face of high blood pressure could cause deleterious effects. In fact, histological examination revealed that GC-A transgenic mice, when crossed with GC-A-deficient animals, displayed multiple focal cardiomyocyte degeneration (data not shown). This alteration in cardiac pathology may offer an explanation for the lack of a significant decrease in cardiac weight in response to expression of the GC-A transgene in null animals.
In the present study, ventricular ANP levels are suppressed in the mice with overexpression of the GC-A gene in either wild-type or GC-A null backgrounds. The decrease in ANP levels coincides with a decrease in cardiomyocyte area and supports work suggesting that ventricular ANP represents an excellent marker for cardiomyocyte hypertrophy (7).
In summary, cardiac overexpression of GC-A reduced cardiomyocyte size and ventricular ANP expression in either wild-type or GC-A null background. The genetic models produced here have separated an indirect regulation of cardiomyocyte size by hemodynamic alteration from a direct regulation by GC-A.
| |
Acknowledgements |
|---|
We thank Drs. Eric Olson and Brian Mercer for their assistance in the production of the transgenic animals.
| |
Abbreviations |
|---|
GC-A, guanylyl cyclase-A; ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide.
| |
Footnotes |
|---|
Current address: Kyoto University Graduate School of
Medicine, Department of Medicine and Clinical Science, 54 Kawahara-cho, Shogoin Sakyo-ku, Kyoto 6068397, Japan.
¶ To whom reprint requests should be addressed at: Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9051. E-mail: dgarbe{at}mednet.swmed.edu.
| |
References |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
| 1. | de Bold, A. J. , Borenstein, H. B. , Veress, A. T. & Sonnenberg, H. (1981) Life Sci. 28, 89-94. |
| 2. | Thibault, G. , Amiri, F. & Garcia, R. (1999) Annu. Rev. Physiol. 61, 193-217. |
| 3. | Ruskoaho, H. (1993) Pharmacol. Rev. 44, 479-602. |
| 4. | Maack, T. (1992) Annu. Rev. Physiol. 54, 11-27. |
| 5. | Steinhelper, M. E. , Cochrane, K. L. & Field, L. J. (1990) Hypertension 16, 301-307. |
| 6. | Brenner, B. M. , Ballermann, B. J. , Gunning, M. E. & Zeidel, M. L. (1990) Physiol. Rev. 70, 665-699. |
| 7. | Garbers, D. L. (1992) Cell 71, 1-4. |
| 8. | Chien, R. (1992) Basic Res. Cardiol. 87, Suppl. 2, 49-58. |
| 9. | Chinkers, M. , Garbers, D. L. , Chang, M. S. , Lowe, D. G. , Chin, H. M. , Goeddel, D. V. & Schulz, S. (1989) Nature (London) 338, 78-83. |
| 10. | Lowe, D. G. , Chang, M. S. , Hellmiss, R. , Chen, E. , Singh, S. , Garbers, D. L. & Goeddel, D. V. (1989) EMBO J. 8, 1377-1384. |
| 11. | Lopez, M. J. , Garbers, D. L. & Kuhn, M. (1997) J. Biol. Chem. 272, 23064-23068. |
| 12. | Kishimoto, I. , Dubois, S. K. & Garbers, D. L. (1996) Proc. Natl. Acad. Sci. USA 93, 6215-6219. |
| 13. | Dubois, S. K. , Kishimoto, I. , Lillis, T. O. & Garbers, D. L. (2000) Proc. Natl. Acad. Sci. USA 97, 4369-4373. |
| 14. | John, S. W. , Krege, J. H. , Oliver, P. M. , Hagaman, J. R. , Hodgin, J. B. , Panag, S. C. , Flynn, T. G. & Smithies, O. (1995) Science 267, 679-681. |
| 15. | Tamura, N. , Ogawa, Y. , Chusho, H. , Nakamura, K. , Nakao, K. , Suda, M. , Kasahara, M. , Hashimoto, R. , Katsuura, G. , Mukoyama, M. , et al. (2000) Proc. Natl. Acad. Sci. USA 97, 4239-4244. (First Published March 28, 2000; 10.1073/pnas.070371497) |
| 16. | Lopez, M. J. , Wong, S. K. , Kishimoto, I. , Dubois, S. , Mach, V. , Friesen, J. , Garbers, D. L. & Beuve, A. (1995) Nature (London) 378, 65-68. |
| 17. | Oliver, P. M. , Fox, J. E. , Kim, R. , Rockman, H. A. , Kim, H. S. , Reddick, R. L. , Pandy, K. N. , Milgram, S. L. , Smithies, O. & Maeda, N. (1997) Proc. Natl. Acad. Sci. USA 94, 14730-14735. |
| 18. | Garbers, D. L. & Dubois, S. K. (1999) Annu. Rev. Biochem. 68, 127-155. |
| 19. | Horio, T. , Nishikimi, T. , Yoshihara, F. , Matsuo, H. , Takishita, S. & Kangawa, K. (2000) Hypertension 35, 19-24. |
| 20. | Clemo, H. F. & Baumgarten, C. M. (1995) Circ. Res. 77, 741-749. |
| 21. | Clemo, H. F. , Feher, J. J. & Baumgarten, C. M. (1992) J. Gen. Physiol. 100, 89-114. |
| 22. | Clemo, H. F. & Baumgarten, C. M. (1991) Am. J. Physiol. 260, C681-C690. |
| 23. | Gulick, J. , Subramaniam, A. , Neumann, J. & Robbins, J. (1991) J. Biol. Chem. 266, 9180-9185. |
| 24. | Robbins, J. (2000) Annu. Rev. Physiol. 62, 261-287. |
| 25. | Milano, C. A. , Allen, L. F. , Rockman, H. A. , Dolber, P. C. , McMinn, T. R. , Chien, K. R. , Johnson, T. D. , Bond, R. A. & Lefkowitz, R. J. (1994) Science 264, 582-586. |
| 26. | Ng, W. A. , Grupp, I. L. , Subramaniam, A. & Robbins, J. (1991) Circ. Res. 68, 1742-1750. |
| 27. | Palermo, J. , Gulick, J. , Colbert, M. , Fewell, J. & Robbins, J. (1996) Circ. Res. 78, 504-509. |
| 28. | Wolska, B. M. & Solaro, R. J. (1996) Am. J. Physiol. 271(3 Part 2), H1250-H1255. |
| 29. | de Bold, A. J. , Bruneau, B. G. & Kuroski de Bold, M. L. (1996) Cardiovasc. Res. 31, 7-18. |
| 30. | Izumo, S. , Nadal-Ginard, B. & Mahdavi, V. (1988) Proc. Natl. Acad. Sci. USA 85, 339-343. |
| 31. | Bloch, K. D. , Seidman, J. G. , Naftilan, J. D. , Fallon, J. T. & Seidman, C. E. (1986) Cell 47, 695-702. |
| 32. | Steinhelper, M. E. , Cochrane, K. L. & Field, L. J. (1990) Hypertension 16, 301-307. |
| 33. | Ogawa, Y. , Itoh, H. , Tamura, N. , Suga, S. , Yoshimasa, T. , Uehira, M. , Matsuda, S. , Shiono, S. , Nishimoto, H. & Nakao, K. (1994) J. Clin. Invest. 93, 1911-1921. |
| 34. | Fujisaki, H. , Ito, H. , Hirata, Y. , Tanaka, M. , Hata, M. , Lin, M. , Adachi, S. , Akimoto, H. , Marumo, F. & Hiroe, M. (1995) J. Clin. Invest. 96, 1059-1065. |
| 35. | Pandey, K. N. , Nguyen, H. T. , Li, M. & Boyle, J. W. (2000) Biochem. Biophys. Res. Commun. 271, 374-379. |
| 36. | Itoh, H. , Pratt, R. E. , Ohno, M. & Dzau, V. J. (1992) Hypertension 19, 758-761. |
| 37. | Chrisman, T. D. & Garbers, D. L. (1999) J. Biol. Chem. 274, 4293-4299. |
| 38. | Chusho, H. , Ogawa, Y. , Tamura, N. , Suda, M. , Yasoda, A. , Miyazawa, T. , Kishimoto, I. , Komatsu, Y. , Itoh, H. , Tanaka, K. , et al. (2000) Endocrinology 141, 3807-3813. |
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg What's this?
This article has been cited by other articles in HighWire Press-hosted journals:
|
|
 |
|
  T. Tokudome, I. Kishimoto, T. Horio, Y. Arai, D. O. Schwenke, J. Hino, I. Okano, Y. Kawano, M. Kohno, M. Miyazato, et al. Regulator of G-Protein Signaling Subtype 4 Mediates Antihypertrophic Effect of Locally Secreted Natriuretic Peptides in the Heart Circulation, May 6, 2008; 117(18): 2329 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. William, E. J. Hamilton, A. Garcia, H. Bundgaard, K. K. M. Chia, G. A. Figtree, and H. H. Rasmussen Natriuretic peptides stimulate the cardiac sodium pump via NPR-C-coupled NOS activation Am J Physiol Cell Physiol, April 1, 2008; 294(4): C1067 - C1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass, H. C. Champion, and J. A. Beavo Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation Circ. Res., November 26, 2007; 101(11): 1084 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vandeput, S. L. Wolda, J. Krall, R. Hambleton, L. Uher, K. N. McCaw, P. B. Radwanski, V. Florio, and M. A. Movsesian Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes J. Biol. Chem., November 9, 2007; 282(45): 32749 - 32757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Vellaichamy, D. Zhao, N. Somanna, and K. N. Pandey Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy Physiol Genomics, October 19, 2007; 31(2): 193 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kilic, A. Bubikat, B. Gassner, H. A. Baba, and M. Kuhn Local Actions of Atrial Natriuretic Peptide Counteract Angiotensin II Stimulated Cardiac Remodeling Endocrinology, September 1, 2007; 148(9): 4162 - 4169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Murray, J. D. Gardner, S. P. Levick, G. L. Brower, L. G. Morgan, and J. S. Janicki Response of cardiac mast cells to atrial natriuretic peptide Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1216 - H1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass, E. Takimoto, T. Nagayama, and H. C. Champion Phosphodiesterase regulation of nitric oxide signaling Cardiovasc Res, July 15, 2007; 75(2): 303 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Dickey, D. R. Flora, P. M. Bryan, X. Xu, Y. Chen, and L. R. Potter Differential Regulation of Membrane Guanylyl Cyclases in Congestive Heart Failure: Natriuretic Peptide Receptor (NPR)-B, Not NPR-A, Is the Predominant Natriuretic Peptide Receptor in the Failing Heart Endocrinology, July 1, 2007; 148(7): 3518 - 3522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zaccolo and M. A. Movsesian cAMP and cGMP Signaling Cross-Talk: Role of Phosphodiesterases and Implications for Cardiac Pathophysiology Circ. Res., June 8, 2007; 100(11): 1569 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Rame, M. H. Drazner, W. Post, R. Peshock, J. Lima, R. S. Cooper, and D. L. Dries Corin I555(P568) Allele Is Associated With Enhanced Cardiac Hypertrophic Response to Increased Systemic Afterload Hypertension, April 1, 2007; 49(4): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yurukova, A. Kilic, K. Volker, K. Leineweber, N. Dybkova, L. S. Maier, O.-E. Brodde, and M. Kuhn CaMKII-mediated increased lusitropic responses to {beta}-adrenoreceptor stimulation in ANP-receptor deficient mice Cardiovasc Res, March 1, 2007; 73(4): 678 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Gardner, S. Chen, D. J. Glenn, and C. L. Grigsby Molecular Biology of the Natriuretic Peptide System: Implications for Physiology and Hypertension Hypertension, March 1, 2007; 49(3): 419 - 426. [Full Text] [PDF]
|
|
|
|
|
|
E. Takimoto and D. A. Kass Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling Hypertension, February 1, 2007; 49(2): 241 - 248. [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, S. Hashim, and M. B. Anand-Srivastava Intracellular peptides of natriuretic peptide receptor-C inhibit vascular hypertrophy via Gq{alpha}/MAP kinase signaling pathways Cardiovasc Res, December 1, 2006; 72(3): 464 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Laskowski, O. L. Woodman, A. H. Cao, G. R. Drummond, T. Marshall, D. M. Kaye, and R. H. Ritchie Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes Cardiovasc Res, October 1, 2006; 72(1): 112 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. London Natriuretic Peptides and Cardiac Hypertrophy J. Am. Coll. Cardiol., August 1, 2006; 48(3): 506 - 507. [Full Text] [PDF]
|
|
|
|
|
|
S. Rubattu, G. Bigatti, A. Evangelista, C. Lanzani, R. Stanzione, L. Zagato, P. Manunta, S. Marchitti, V. Venturelli, G. Bianchi, et al. Association of Atrial Natriuretic Peptide and Type A Natriuretic Peptide Receptor Gene Polymorphisms With Left Ventricular Mass in Human Essential Hypertension J. Am. Coll. Cardiol., August 1, 2006; 48(3): 499 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Margulies and J. C. Burnett Jr Visualizing the basis for paracrine natriuretic peptide signaling in human heart. Circ. Res., July 21, 2006; 99(2): 113 - 115. [Full Text] [PDF]
|
|
|
|
|
|
G. Singh, R. E. Kuc, J. J. Maguire, M. Fidock, and A. P. Davenport Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart: Downregulation of Natriuretic Peptide Receptor-A in Heart Failure Circ. Res., July 21, 2006; 99(2): 183 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Langenickel, J. Buttgereit, I. Pagel-Langenickel, M. Lindner, J. Monti, K. Beuerlein, N. Al-Saadi, R. Plehm, E. Popova, J. Tank, et al. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B PNAS, March 21, 2006; 103(12): 4735 - 4740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, T. R. Kimball, J. N. Lorenz, D. A. Brown, A. R. Bauskin, R. Klevitsky, T. E. Hewett, S. N. Breit, and J. D. Molkentin GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein Activation Circ. Res., February 17, 2006; 98(3): 342 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Potter, S. Abbey-Hosch, and D. M. Dickey Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions Endocr. Rev., February 1, 2006; 27(1): 47 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nishikimi, N. Maeda, and H. Matsuoka The role of natriuretic peptides in cardioprotection Cardiovasc Res, February 1, 2006; 69(2): 318 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Hofmann, R. Feil, T. Kleppisch, and J. Schlossmann Function of cGMP-Dependent Protein Kinases as Revealed by Gene Deletion Physiol Rev, January 1, 2006; 86(1): 1 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hambleton, J. Krall, E. Tikishvili, M. Honeggar, F. Ahmad, V. C. Manganiello, and M. A. Movsesian Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium J. Biol. Chem., November 25, 2005; 280(47): 39168 - 39174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Luo, J. R. McMullen, C. L. Sobkiw, L. Zhang, A. L. Dorfman, M. C. Sherwood, M. N. Logsdon, J. W. Horner, R. A. DePinho, S. Izumo, et al. Class IA Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy Mol. Cell. Biol., November 1, 2005; 25(21): 9491 - 9502. [Abstract] [Full Text] [PDF]
|
|
).
